Herbal Medicine Use in CKD Patients on Réunion Island
Official title: Prospective Analysis of Self Medication With Phytotherapy in Nephropatic Patients.
Run by Centre Hospitalier Universitaire de la Réunion · NCT07444515 · Data updated 2026-11-12
This study tests how common herbal medicine use is among adults with chronic kidney disease (stages 3–5) on Réunion Island and whether it relates to kidney disease progression over a year.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 400 (estimated) |
| Sponsor | Centre Hospitalier Universitaire de la Réunion Academic / other |
| Locations | 4 sites (Saint-Benoît and 3 other locations) |
| Status | Recruiting |
| Started | July 28, 2026 |
| Main results expected | July 28, 2027 |
| Study ends | August 28, 2028 |
| Registry record updated | September 16, 2026 |
| Trial ID | NCT07444515 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with CKD stage 3–5 (not on dialysis) living on Réunion Island and under nephrology care, able to complete a questionnaire, and enrolled for one year.
✕Probably not a fit
Patients not using herbal medicines or with CKD progression unrelated to phytotherapy may not experience a direct benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional study collects data via questionnaires from adults with CKD stages 3–5 who are under nephrology care on Réunion Island. The goal is to describe how many patients use phytotherapy and to explore any association between specific herbs and CKD progression over 12 months. Participants are identified through routine nephrology follow-up and complete questionnaires at enrolled centers. The study focuses on real-world use of traditional plant-based therapies and their potential impact on kidney health. No randomization or placebo control is involved; the emphasis is observational within an interventional data-collection framework.
Why it matters
Potential benefit: If phytotherapy use can be linked to disease progression or safety signals, patients and clinicians could make better-informed treatment choices.
How similar studies have gone: There is limited data on phytotherapy use in CKD; this study would add real-world insights but similar large-scale analyses are scarce.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Individual: * Adult * Resident of Réunion Island and planning to remain on the island for the year following enrollment * Chronic Kidney Disease Stage 3, 4, or 5, not on dialysis * Under the care of a nephrologist * Able to complete a questionnaire * Registered with social security Exclusion Criteria: Individual: * Kidney transplant recipient * Adult under guardianship or legal protection * Pregnant or breastfeeding women, or women planning a pregnancy during the enrollment period
Where it's running
-
Groupe Hospitalier Est Réunion
Saint-Benoît, France Recruiting -
CHU Reunion site 1
Saint-Denis, France Recruiting -
Aurar
Saint-Paul, France Recruiting -
CHU Reunion site 2
Saint-Pierre, France Recruiting
Study contacts
- Study coordinator: Hospital promotion
- Email: promotion.drci@chu-reunion.fr
- Phone: 0262359000
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
ACE Reno Pico Cell Matrix for reducing proteinuria and supporting kidney function
This trial will test whether taking ACE Reno, a sublingual peptide solution four times daily for 12 weeks, can lower urine protein and help stabilize kidney function in adults with nephropathy or chronic kidney disease.
-
Synbiotic Therapy for Kidney Function in CKD Stage III-IV
This study tests whether a synbiotic (probiotics plus prebiotics) can improve kidney function in adults with non-dialysis CKD stage 3-4 compared with a placebo.
-
Primary Palliative Care: A Feasibility Project for Family Health Units
This feasibility trial tests a GP training program plus a structured 12-week palliative-care visit plan to see if it can be carried out in primary care for adults with advanced illness.
-
Synbiotic capsules for adults on peritoneal dialysis
This study tests whether daily synbiotic capsules can reduce inflammation and improve nutrition in adults with CKD on peritoneal dialysis compared with a placebo.
-
Potassium-friendly plant-based diet for people with advanced CKD
This pilot study tests whether a liberal plant-based diet with normal potassium levels is safe and acceptable for adults with advanced CKD (eGFR <30) who are not on dialysis.
-
Perirenal SC101 injection to lower blood pressure in resistant hypertension with moderate–severe CKD
This trial will test whether a single injection of SC101 into the fat around the kidneys can lower blood pressure in adults with resistant hypertension and stage 3–4 chronic kidney disease.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.